awmsg logo



maraviroc (Celsentri®)


Reference No. 344

Publication date:
11/06/2009


Appraisal information

maraviroc (Celsentri®) film-coated tablet


Company: Pfizer Ltd
BNF category: Infections
NMG meeting date: 25/03/2009
AWMSG meeting date: 29/04/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0709
Ministerial ratification: 10/06/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Maraviroc (Celsentri®) is recommended as an option for use within NHS Wales for the treatment of treatment-experienced adults infected only with CCR5-tropic HIV-1, in accordance with British HIV Association (BHIVA) guidance. AWMSG is of the opinion that maraviroc (Celsentri®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download